Inspire Investing 13F: Exits IRWD Stake

Inspire Investing closed out its position in Ironwood Pharmaceuticals, Inc. IRWD, parting ways with all 630,072 shares it held in the company. The complete exit was disclosed in a Form 13F regulatory filing with the Securities and Exchange Commission on October 22, 2026. The stock closed at $3.57 on the day of the filing.

IRWD Ironwood Pharmaceuticals, Inc.

$3.46 ▼ -18.97% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Inspire Investing's Ironwood Pharmaceuticals Position

Inspire Investing completely liquidated its holdings in Ironwood Pharmaceuticals, Inc. IRWD during the period, bringing its share count from 630,072 down to zero. Because this was a complete exit, the fund shed 100% of its stake. The move leaves the fund with no remaining exposure to the specialty drug developer.

Other Institutional Activity in Ironwood Pharmaceuticals

Other large funds also made notable adjustments to their Ironwood Pharmaceuticals portfolios. Armistice Capital, LLC reduced its holdings by 1,095,505 shares, ending with 13,932,000 shares worth about $48,204,720. Sarissa Capital Management, LP kept its position steady at 9,188,635 shares valued at about $31,792,677 with zero net change. Renaissance Technologies, LLC grew its holdings by trimming 67,712 shares, closing the period with 7,993,226 shares worth about $27,656,562. AQR Capital Management, LLC cut its position by 1,069,239 shares, holding 6,465,921 shares worth about $22,372,086. Acadian Asset Management. LLC reduced its stake by 724,184 shares, resulting in 5,853,331 shares worth about $20,252,525.

Ironwood Pharmaceuticals, Inc. Stock Down 2.5%

Ironwood Pharmaceuticals, Inc. IRWD recently traded around $3.46 as of October 24, 2026, sitting about 3.1% below its $3.57 close on the filing date. The stock has traded between a 52-week low of $1.47 and a 52-week high of $5.78.

Recent Earnings

Ironwood Pharmaceuticals, Inc. IRWD generated $389,316,000 in trailing twelve-month revenue with an earnings per share of $0.77. The company posted a net profit margin of 33.4% and an annual revenue growth rate of 32.6%. The company is scheduled to report its next financial results on November 9, 2026.

Insider Buying and Selling at Ironwood Pharmaceuticals, Inc.

Insider activity at Ironwood Pharmaceuticals, Inc. IRWD included several transactions prior to the filing. On June 16, 2026, Julie Mchugh sold 21,571 shares at an average price of $3.73 totaling $80,459.83 in a transaction under a Rule 10b5-1 plan. On the same date, Mark Currie acquired 63,481 shares, Julie Mchugh acquired 63,481 shares, and Jon Duane acquired 63,481 shares.

Analysts Set New Price Targets

Analyst coverage includes a consensus rating alongside a mean price target of $6.10 across four analyst opinions.

About Ironwood Pharmaceuticals

Based in Boston, Massachusetts, Ironwood Pharmaceuticals, Inc. IRWD is a biotechnology firm focused on creating and commercializing medical treatments for gastrointestinal disorders and rare diseases. The company works to bring specialized therapies to patients in domestic and international markets.

Bottom Line

Investors continue to monitor institutional portfolio shifts as Ironwood Pharmaceuticals, Inc. IRWD prepares for its upcoming financial report in November. The complete exit by Inspire Investing highlights shifting sentiment among institutional holders of the stock.